A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers

An Open-label, Fixed-sequence, 3-period Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07784608

Acronym

DDI

Enrollment

Registered

2026-08-25

Start date

2026-09-01

Completion date

2027-11-01

Last updated

2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-drug Interactions

Keywords

Drug-Drug Interactions

Brief summary

This study aims to evaluate the pharmacokinetic interactions between HUC2-744-A and HUC2-744-B following monotherapy or co-administration under multiple-dose conditions.

Detailed description

For selected subjects, the designated investigational products are administered orally with 200 mL of water during Treatment 1 (HUC2-744-A), Treatment 2 (HUC2-744-B), and Treatment 3 (HUC2-744-A + HUC2-744-B).

Interventions

DRUGAtorvastatin Calcium

HUC2-744-A

DRUGTelmisartan

HUC2-744-B

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adults * Subjects with a body weight of 50 kg or more and a BMI within the range of 18.0 to 29.9 kg/m²

Exclusion criteria

* History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease * Presence of acute disease symptoms within 28 days prior to the first dosing * History of any disease that may affect drug absorption, distribution, metabolism, or excretion * Hypersensitivity or history of clinically significant hypersensitivity to atorvastatin, telmisartan, drugs containing ingredients of the same class, or other medications (e.g., aspirin, antibiotics, dihydropyridine derivatives)

Design outcomes

Primary

Measure	Time frame	Description
AUCτ	Day 22	Area Under the Curve of telmisartan, atorvastatin
Cmax,ss	Day 22	Maximum concentration at steady state of telmisartan, atorvastatin

Secondary

Measure	Time frame	Description
Cmax,ss	Day 22	Maximum concentration at steady state of 2-hydroxy atorvastatin
AUCτ	Day 22	Area Under the Curve of 2-hydroxy atorvastatin

Countries

South Korea

Contacts

CONTACTHuons

jywon@huons.com+82-70-7492-6023

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026